Cetrorelix vs PT-141

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context In IVF, cetrorelix is used under two standard protocols. The multiple-dose protocol administers 0.25mg subcutaneously once daily starting from stimulation day 5 or 6, continuing until the day of oocyte trigger — this prevents LH surge during the follicular growth phase. The single-dose protocol administers 3mg once when the leading follicle reaches approximately 14mm, providing LH suppression for approximately 96 hours; a supplemental 0.25mg dose is added if trigger has not occurred by day 4. Both protocols have established efficacy data and are used depending on clinic preference and patient response characteristics. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.

PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist and the first centrally acting peptide approved by the FDA for a sexual dysfunction indication — marketed as Vyleesi (Palatin Technologies / AMAG Pharmaceuticals) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike phosphodiesterase-5 inhibitors such as sildenafil, which act peripherally through vascular smooth muscle relaxation, PT-141 acts centrally via melanocortin MC3R and MC4R receptors in the hypothalamus to modulate sexual motivation and arousal pathways — a mechanistically distinct approach that is effective regardless of vascular status. Pivotal Phase 3 RCTs in premenopausal women with HSDD demonstrated statistically significant improvements in satisfying sexual events and desire scores versus placebo, establishing the clinical evidence base for FDA approval in 2019. PT-141 dosage: the FDA-approved dose is 1.75mg administered as a single subcutaneous injection in the abdomen using an auto-injector device, approximately 45 minutes before anticipated sexual activity; it should not be used more than once per 24 hours or more than 8 times per month per prescribing guidance. Compounded PT-141 — available through licensed compounding pharmacies — is commonly prepared in 10mg vials for research contexts; typical compounded doses range from 1–2mg per use. PT-141 nasal spray formulations have been investigated as an alternative delivery route, though the approved form is subcutaneous injection. PT-141 for men: while FDA approval is limited to premenopausal women with HSDD, PT-141 is used off-label in men for sexual dysfunction, including cases where PDE5 inhibitors are insufficient or contraindicated; the central mechanism of action is not sex-specific. Side effects: the most common adverse effect is nausea (reported in approximately 40% of subjects in pivotal trials), followed by flushing, headache, and transient hyperpigmentation with repeated use. A transient increase in blood pressure is observed in the first hour post-injection; PT-141 is contraindicated in patients with uncontrolled hypertension or cardiovascular disease. PT-141 (Vyleesi) is FDA-approved and requires a prescription; compounding pharmacy access also requires a prescription. Providers offering PT-141 consultations — including telehealth platforms — can be found in the PeptideBase directory.